Is Budd-Chiari Syndrome hereditary?

Budd-Chiari syndrome is generally not considered a hereditary disease, as it is typically caused by acquired factors that lead to blood clots in the hepatic veins. While it is rarely inherited directly, individuals may have an underlying genetic predisposition to blood clotting (thrombophilia) that significantly increases their risk of developing Budd-Chiari syndrome.

Is Budd-Chiari syndrome a genetic or hereditary condition?

It is important to distinguish between "genetic" and "hereditary." Budd-Chiari syndrome is primarily an acquired condition where blood flow out of the liver is obstructed. It is not inherited in a classic Mendelian pattern (like autosomal dominant or recessive). However, many patients diagnosed with Budd-Chiari syndrome possess underlying inherited thrombophilias—genetic mutations that make the blood more prone to clotting. Therefore, while the syndrome itself is not passed down as a single genetic trait, the susceptibility factors that contribute to it often have a strong genetic component.

What are the risk factors and genetic associations?

The development of Budd-Chiari syndrome is often multifactorial, involving the interplay between acquired triggers and genetic risk factors. Common genetic predispositions identified in patients include:

• Factor V Leiden mutation: A common genetic variation that increases the risk of venous thrombosis.


• Prothrombin G20210A mutation: A genetic change that leads to higher levels of prothrombin, increasing clot risk.


• Protein C and Protein S deficiencies: Inherited conditions where the body lacks the proteins necessary to prevent excessive clotting.


• Antithrombin deficiency: A rare hereditary condition that causes the blood to clot more easily than normal.


• JAK2 V617F mutation: Frequently associated with myeloproliferative neoplasms, which are a major primary cause of Budd-Chiari syndrome.

Is genetic testing recommended for patients?

Genetic testing is not used to diagnose Budd-Chiari syndrome itself, but it is standard practice to screen for underlying thrombophilias once the syndrome is confirmed. A hematologist or clinical geneticist may recommend testing to identify these underlying factors, as this information is vital for long-term management and anticoagulation therapy. Because Budd-Chiari syndrome is often linked to these specific mutations, identifying them helps clinicians understand the patient’s overall risk profile for future clotting events.

What is the role of genetic counseling for families?

Genetic counseling is highly recommended for families where multiple members have a history of unexplained blood clots or Budd-Chiari syndrome. A genetic counselor can help determine if a hereditary thrombophilia runs in the family. While there is no "percentage risk" for a child inheriting the syndrome itself, children of parents with certain thrombophilias may have an increased risk of developing clotting disorders. Counseling provides clarity on whether family members should undergo cascade testing to assess their own risk of thrombosis.

Next steps

• Consult with a hematologist or hepatologist to discuss testing for underlying thrombophilias.


• Connect with the 48 members of the DiseaseMaps.org community to share experiences regarding diagnosis and management.


• If a hereditary mutation is identified, request a referral to a genetic counselor to discuss implications for other family members.


• Keep a detailed record of your family's history of blood clots or liver-related conditions to share with your medical team.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center - Budd-Chiari Syndrome.


• Orphanet: Portal for rare diseases and orphan drugs (ORPHA:132).


• OMIM (Online Mendelian Inheritance in Man): Thrombophilia and venous thromboembolism research.


• American Association for the Study of Liver Diseases (AASLD) guidelines on vascular liver disorders.